Association of GLP-1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta-Analysis

IF 4.6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Ganesh Bushi, Mahalaqua Nazli Khatib, Shivam Rohilla, Mahendra Pratap Singh, Nidhi Uniyal, Suhas Ballal, Pooja Bansal, Kiran Bhopte, Manika Gupta, Abhay M. Gaidhane, Balvir S. Tomar, Ayash Ashraf, M. Ravi Kumar, Ashish Singh Chauhan, Sanjit Sah, Hashem Abu Serhan, Muhammed Shabil
{"title":"Association of GLP-1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta-Analysis","authors":"Ganesh Bushi,&nbsp;Mahalaqua Nazli Khatib,&nbsp;Shivam Rohilla,&nbsp;Mahendra Pratap Singh,&nbsp;Nidhi Uniyal,&nbsp;Suhas Ballal,&nbsp;Pooja Bansal,&nbsp;Kiran Bhopte,&nbsp;Manika Gupta,&nbsp;Abhay M. Gaidhane,&nbsp;Balvir S. Tomar,&nbsp;Ayash Ashraf,&nbsp;M. Ravi Kumar,&nbsp;Ashish Singh Chauhan,&nbsp;Sanjit Sah,&nbsp;Hashem Abu Serhan,&nbsp;Muhammed Shabil","doi":"10.1002/dmrr.70037","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Objective</h3>\n \n <p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used to treat type 2 diabetes and obesity, providing metabolic and cardiovascular benefits. However, concerns have emerged about potential neuropsychiatric side effects, including suicidal ideation and behaviour, prompting investigations by regulatory bodies such as the FDA and EMA. This systematic review and meta-analysis aimed to assess the association between GLP-1RA use and the risk of suicidal ideation or behaviour.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A systematic literature search was conducted in PubMed, Embase, and Web of Science through September 2024, adhering to PRISMA guidelines. Observational cohort and case-control studies reporting suicidal ideation or behaviour in adults using GLP-1RAs were included. The Modified Newcastle-Ottawa Scale assessed risk of bias, and random-effect models calculated risk ratios (RR) with 95% confidence intervals (CIs). Heterogeneity was assessed using the I<sup>2</sup> statistic.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of 126 studies, 11 were included from multiple countries with diverse designs. The meta-analysis of four studies showed no statistically significant difference in suicidal outcomes between GLP-1RA users and users of other anti-hyperglycaemic drugs (RR: 0.568, 95% CI: 0.077–4.205). Substantial heterogeneity was observed (I<sup>2</sup> = 98%). Pharmacovigilance studies indicated no disproportionate increase in suicidality, while some observational studies suggested a lower risk.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This review found no significant link between GLP-1RA use and increased suicidal ideation or behaviour. However, the high heterogeneity and reliance on pharmacovigilance data suggest caution. Clinicians should monitor patients, particularly those with psychiatric conditions, and further research is needed to assess long-term neuropsychiatric safety.</p>\n </section>\n </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 2","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70037","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes/Metabolism Research and Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/dmrr.70037","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background and Objective

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used to treat type 2 diabetes and obesity, providing metabolic and cardiovascular benefits. However, concerns have emerged about potential neuropsychiatric side effects, including suicidal ideation and behaviour, prompting investigations by regulatory bodies such as the FDA and EMA. This systematic review and meta-analysis aimed to assess the association between GLP-1RA use and the risk of suicidal ideation or behaviour.

Methods

A systematic literature search was conducted in PubMed, Embase, and Web of Science through September 2024, adhering to PRISMA guidelines. Observational cohort and case-control studies reporting suicidal ideation or behaviour in adults using GLP-1RAs were included. The Modified Newcastle-Ottawa Scale assessed risk of bias, and random-effect models calculated risk ratios (RR) with 95% confidence intervals (CIs). Heterogeneity was assessed using the I2 statistic.

Results

Of 126 studies, 11 were included from multiple countries with diverse designs. The meta-analysis of four studies showed no statistically significant difference in suicidal outcomes between GLP-1RA users and users of other anti-hyperglycaemic drugs (RR: 0.568, 95% CI: 0.077–4.205). Substantial heterogeneity was observed (I2 = 98%). Pharmacovigilance studies indicated no disproportionate increase in suicidality, while some observational studies suggested a lower risk.

Conclusion

This review found no significant link between GLP-1RA use and increased suicidal ideation or behaviour. However, the high heterogeneity and reliance on pharmacovigilance data suggest caution. Clinicians should monitor patients, particularly those with psychiatric conditions, and further research is needed to assess long-term neuropsychiatric safety.

Abstract Image

GLP-1受体激动剂与自杀意念和行为风险的关联:一项系统综述和荟萃分析
背景与目的胰高血糖素样肽-1受体激动剂(Glucagon-like peptide-1 receptor agonists, GLP-1RAs)广泛用于治疗2型糖尿病和肥胖症,具有代谢和心血管方面的益处。然而,对潜在的神经精神副作用的担忧已经出现,包括自杀意念和行为,促使FDA和EMA等监管机构进行调查。本系统综述和荟萃分析旨在评估GLP-1RA使用与自杀意念或行为风险之间的关系。方法按照PRISMA指南,于2024年9月在PubMed、Embase和Web of Science中进行系统的文献检索。报告使用GLP-1RAs的成人自杀意念或行为的观察性队列研究和病例对照研究被纳入。修正纽卡斯尔-渥太华量表评估偏倚风险,随机效应模型以95%置信区间(ci)计算风险比(RR)。采用I2统计量评估异质性。结果在126项研究中,有11项研究来自多个国家,采用不同的设计。四项研究的荟萃分析显示,GLP-1RA服用者与其他降糖药物服用者的自杀结局无统计学差异(RR: 0.568, 95% CI: 0.077-4.205)。观察到大量异质性(I2 = 98%)。药物警戒研究表明自杀率没有不成比例的增加,而一些观察性研究表明风险较低。结论:本综述未发现GLP-1RA使用与自杀意念或行为增加之间存在显著联系。然而,高度异质性和对药物警戒数据的依赖提示谨慎。临床医生应该监测患者,特别是那些有精神疾病的患者,并且需要进一步的研究来评估长期的神经精神病学安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes/Metabolism Research and Reviews
Diabetes/Metabolism Research and Reviews 医学-内分泌学与代谢
CiteScore
17.20
自引率
2.50%
发文量
84
审稿时长
4-8 weeks
期刊介绍: Diabetes/Metabolism Research and Reviews is a premier endocrinology and metabolism journal esteemed by clinicians and researchers alike. Encompassing a wide spectrum of topics including diabetes, endocrinology, metabolism, and obesity, the journal eagerly accepts submissions ranging from clinical studies to basic and translational research, as well as reviews exploring historical progress, controversial issues, and prominent opinions in the field. Join us in advancing knowledge and understanding in the realm of diabetes and metabolism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信